Sugi Predict

Sugi Predict / Compounds / SCHEMBL9312422

SCHEMBL9312422

SCHEMBL9312422

O=C(c1ccccc1F)C(F)F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES2 O00748 4/20 0.60
▸ CES1 P23141 4/20 0.60
▸ ALDH1A1 P00352 2/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ GAA P10253 1/20 0.50
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ NPC1 O15118 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ PTPN1 P18031 1/20 0.46
▸ ERCC5 P28715 1/20 0.46
▸ FEN1 P39748 1/20 0.46
▸ BCHE P06276 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ ALB P02768 1/20 0.42
▸ HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30682655 1.00 CES2 (0.60) CES2CES1ALDH1A1ALOX15GAA
SCHEMBL30081002 0.86 CES2 (0.60) CES2CES1ALDH1A1ALOX15GAA
SCHEMBL4598915 0.84 CES2 (0.53) CES2CES1ALDH1A1ALOX15GAA
SCHEMBL1743417 0.83 CES2 (0.56) CES2CES1ALDH1A1ALOX15GAA
SCHEMBL5224837 0.83 CES2 (0.56) CES2CES1ALDH1A1ALOX15GAA
SCHEMBL10325438 0.83 CES2 (0.63) CES2CES1ALDH1A1ALOX15GAA
SCHEMBL9861760 0.80 ALDH1A1 (0.59) CES2CES1ALDH1A1ALOX15GAA
SCHEMBL30712874 0.80 CES2 (0.58) CES2CES1ALDH1A1ALOX15GAA
SCHEMBL888679 0.80 CES2 (0.58) CES2CES1ALDH1A1ALOX15GAA
SCHEMBL30081009 0.80 CES2 (0.58) CES2CES1ALDH1A1ALOX15GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12338262-B2 Modulators of TNF-alpha activity FORWARD THERAPEUTICS, INC. (US) 2025-06-24 — — US disclosed
US-20240279258-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. 2024-08-22 — — US disclosed
US-11987597-B2 Modulators of TNF-α activity FORWARD THERAPEUTICS, INC. (US) 2024-05-21 — — US disclosed
US-20240076306-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. 2024-03-07 — — US disclosed
WO-2023240253-A2 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
WO-2023240253-A2 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
US-10603310-B2 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors H. LUNDBECK A/S (DK) 2020-03-31 — — US disclosed
CN-107074836-B 2-amino-6- (difluoromethyl) -5, 5-difluoro-6-phenyl-3, 4,5, 6-tetrahydropyridine as BACE1 inhibitor H.隆德贝克有限公司 2020-03-27 — — CN disclosed
EP-3461483-A1 SOLID DOSAGE FORMS OF 2-AMINO-6-(DIFLUOROMETHYL)-5,5-DIFLUORO-6-PHENYL-3,4,5,6- TETRAHYDROPYRIDINE BACE1 INHIBITORS H. Lundbeck A/S (DK) 2019-04-03 — — EP disclosed
EP-3461483-A1 SOLID DOSAGE FORMS OF 2-AMINO-6-(DIFLUOROMETHYL)-5,5-DIFLUORO-6-PHENYL-3,4,5,6- TETRAHYDROPYRIDINE BACE1 INHIBITORS H. Lundbeck A/S (DK) 2019-04-03 — — EP disclosed
US-20160130267-A1 2-Amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 Inhibitors H. LUNDBECK A/S (DK) 2016-05-12 — — US disclosed
US-20150266865-A1 DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2015-09-24 — — US disclosed
US-20150266865-A1 DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2015-09-24 — — US disclosed
US-9067926-B2 Fluoromethyl-5,6-dihydro-4H-[1,3]OXAZINES HOFFMANN-LA ROCHE INC. (US) 2015-06-30 — — US disclosed
US-20150031690-A1 FLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZINES F. HOFFMANN-LA ROCHE AG (CH) 2015-01-29 — — US disclosed
EP-2807155-A1 FLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZINES F.HOFFMANN-LA ROCHE AG (CH) 2014-12-03 — — EP disclosed
WO-2014065434-A1 DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2014-05-01 — — WO disclosed
WO-2013110622-A1 FLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZINES F. HOFFMANN-LA ROCHE AG (CH) 2013-08-01 — — WO disclosed
US-5298601-A Heat resistant fluorinated polyimides with aromatic rings UNITED TECHNOLOGIES CORPORATION (US) 1994-03-29 — — US disclosed
US-5298600-A 1-trifluoromethane-3-benzene-2,2'-dibiphenyltracarboxylic acid and an aliphatic or aromatic diamine monomers UNITED TECHNOLOGIES CORPORATION (US) 1994-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10603310-B2 2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors BACE1, BACE2, APP CES2 454/4885CES1 269/4885ALDH1A1 458/4885
US-20150031690-A1 FLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZINES BACE1, BACE2, PSEN1 CES2 530/4885CES1 304/4885ALDH1A1 89/4885
US-20240279258-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, TNFRSF1A, NFKBIA CES2 3419/4885CES1 598/4885ALDH1A1 2706/4885
US-11987597-B2 Modulators of TNF-α activity TNF, TNFRSF1A, NFKBIA CES2 3594/4885CES1 665/4885ALDH1A1 2521/4885
US-20150266865-A1 DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY BACE1, APP, BACE2 CES2 944/4885CES1 806/4885ALDH1A1 1933/4885
US-20240076306-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, TNFRSF1A, NFKBIA CES2 3419/4885CES1 598/4885ALDH1A1 2706/4885
US-20160130267-A1 2-Amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 Inhibitors BACE1, BACE2, APP CES2 700/4885CES1 312/4885ALDH1A1 931/4885
US-12338262-B2 Modulators of TNF-alpha activity TNF, TNFRSF1A, NFKBIA CES2 3419/4885CES1 598/4885ALDH1A1 2706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.